Stents

This channel includes news and new technology innovations for stents, also called vascular scaffolds. Stents are used to help prop open a vessel treated by balloon angioplasty because of the barotrauma caused by the extreme stretching of vessel walls. The stent enables to vessel to heal in an open position with collapsing. Drug eluting stents (DES) are coated in anti-proliferative drugs to precent scar tissue growth which can cause restenosis and occlude the vessel. DES require antiplatelet therapy because the drug carrier polymer on DES can cause thrombus inside the stent, even years after treatment, which is why bare metal stents are still used in some patients. This page includes news on coronary stents, carotid stents, peripheral stents, bioresorbable stents, and renal stents. 

Technology | Stents

April 3, 2019 — The U.S. Food and Drug Administration (FDA) recently granted an additional indication to Bard Peripheral ...

Home April 03, 2019
Home
Technology | Venous Therapies

April 3, 2019 — The U.S. Food and Drug Administration (FDA) recently cleared Bard Peripheral Vascular's Venovo Venous ...

Home April 03, 2019
Home
Technology

April 3, 2019 — Medtronic's Resolute Integrity Zotarolimus-eluting Coronary Stent System received an additional U.S ...

Home April 03, 2019
Home
Feature | Stents | Dave Fornell, Editor

February 22, 2019 — The U.S. Food and Drug Administration (FDA) has approved the Biotronik Orsiro drug-eluting stent ...

Home February 22, 2019
Home
Blog | Cath Lab

Clinical study data makes the world go around in cardiology and is the basis of setting guidelines in evidence-based ...

Home February 20, 2019
Home
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.
Feature | Peripheral Artery Disease (PAD) | Dave Fornell, Editor

In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat peripheral ...

Home January 30, 2019
Home
The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.
Feature | Stents | Dave Fornell, Editor

There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years ago ...

Home January 29, 2019
Home
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.
Feature | Peripheral Artery Disease (PAD) | Dave Fornell, Editor

The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003 ...

Home January 25, 2019
Home
News | Stents

The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few years ...

Home January 22, 2019
Home
News | Peripheral Artery Disease (PAD)

January 17, 2019 — The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers ...

Home January 17, 2019
Home
Blog | Cath Lab

There is a hype cycle surrounding new technologies in all industries, but medicine is unique because of its focus on ...

Home October 16, 2018
Home
Bioresorbable stents (BRS) in development presented by Gregg Stone, M.D., during TCT 2017. Several of the players listed on the slider put their BRS development programs on hold after the negative data from the ABSORB III Trial, but a handful of smaller companies are still pushing the technology forward. #TCT #TCT2018
Feature | Stents Bioresorbable | Dave Fornell, Editor

Bioresorbable stent (BRS) technology is not dead, but the unbridled enthusiasm seen two years ago for the technology has ...

Home October 12, 2018
Home
News | Stents Bioresorbable

October 12, 2018 – Reva Medical presented four key data sets demonstrating the capabilities of the company’s Fantom bior ...

Home October 12, 2018
Home
Videos

Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president, Boston Scientific ...

Home October 11, 2018
Home
Videos

A discussion with Professor Ian Meredith, MBBS, Ph.D., global chief medical officer and executive vice president, Boston ...

Home October 11, 2018
Home
Subscribe Now